Visit Covalon to learn how new compassionate
care technology is protecting patients from infections,
while strengthening patient-centered care.
MISSISSAUGA, ON, Sept. 28,
2022 /CNW/ - Covalon Technologies Ltd. (the "Company"
or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical
technologies company, today announced its participation in the
12th International Pediatric Intestinal Failure and
Rehabilitation Symposium in Toronto from September
30 to October 2, 2022. The meeting brings together health
and science professionals who are dedicated to the care of children
with intestinal failure. Register for the conference and visit
Covalon to learn how Covalon's products are redefining the
standards for compassionate care while helping children heal with
stronger protection from infection.
Conference Details
Dates: Friday, September 30 to Sunday, October 2, 2022
Venue: Sheraton Centre Toronto Hotel (123 Queen St W, Toronto, Ontario, Canada)
Register at:
https://web.cvent.com/event/b32e1c8e-4471-4ba3-b48b-20e65493f7d4
"A single CLABSI can change the course of a patient's treatment
or worse, be life threatening," said Brian
Pedlar, CEO of Covalon. "We need to be more proactive when
it comes to protecting all patients, especially those requiring
long-term I.V. access for survival. Central line–associated
bloodstream infections ("CLABSIs") have increased by 45% during the
COVID-19 pandemic, and by 65% in ICUs.1"
Patients receiving parenteral nutrition (PTN) via central venous
catheter (CVC) are at an increased risk of CLABSI. For these
patients, stable and safe intravenous access is an absolute
requirement for nutritional delivery and survival, both in the
hospital and at home, often for months or years at a
time.2.
While CLABSIs can be life threatening, they are preventable with
the right protocols and the use of CLABSI conscious technology.
Covalon's compassionate care technology solutions for infection
prevention include the following:
- VALGuard® - an FDA listed, transparent, environmental barrier
designed to protect catheter hubs and line connections from
external contaminants and gross contamination, including body
fluids and other secretions. It incorporates a quick-release pull
strip for fast access to infusion hubs and for easy removal.
- IV Clear® - an antimicrobial vascular access dressing that
offers complete transparency at and around the insertion site for
easy daily assessment. It uses a soft silicone adhesive to preserve
the skin's barrier function and minimize skin injuries and
incorporates safe amounts of antimicrobials, without sacrificing
efficacy, to protect against chemical irritation.
- SurgiClear® - is the world's only dual-antimicrobial clear
postoperative dressing that provides full visibility, allowing for
visual surgical site inspection and thus eliminating the need for
early dressing removal.
- CovaClear® IV - uses the same trusted silicone adhesive
technology to protect patients from skin injuries and promote
healing in patients who either don't require, or cannot tolerate,
antimicrobials.
For healthcare providers who are not able to attend the
conference but are interested in learning more about Covalon's
solutions, visit www.covalon.com or follow Covalon on LinkedIn,
Facebook, Instagram or Twitter.
- Centers for Disease Control and Prevention. 2020. National
and State Healthcare-Associated Infections (HAI) Progress
Report. Available at:
https://www.cdc.gov/hai/data/portal/progress-report.html [Accessed
27 September 2022].
- Dissanaike, S., Shelton, M., Warner, K. and O'Keefe, G., 2007.
The risk for bloodstream infections is associated with increased
parenteral caloric intake in patients receiving parenteral
nutrition. Critical Care, 11(5), p.R114.
About Covalon
Covalon Technologies Ltd. is a
researcher, developer, manufacturer, and marketer of
patent-protected medical products that improve patient outcomes and
save lives in the areas of advanced wound care, infection
management and surgical procedures. Covalon leverages its patented
medical technology platforms and expertise in two ways: (i) by
developing products that are sold under Covalon's name; and (ii) by
developing and commercializing medical products for other medical
companies under development and license contracts. The Company is
listed on the TSX Venture Exchange, having the symbol COV and
trades on the OTQX Market under the symbol CVALF. To learn more
about Covalon, visit our website at www.covalon.com
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
This news release may contain forward-looking statements
which reflect the Company's current expectations regarding future
events. The forward-looking statements are often, but not always,
identified by the use of words such as "seek", "anticipate", "plan,
"estimate", "expect", "intend" or variations of such words and
phrases or state that certain actions, events or results "may",
"could", "would", "might", "will" or "will be taken", "occur" or
"be achieved". In addition, any statements that refer to
expectations, projections or other characterizations of future
events or circumstances contain forward-looking information.
Statements containing forward-looking information are not
historical facts, but instead represent management's expectations,
estimates and projections regarding future events. Forward-looking
statements involve risks and uncertainties, including, but not
limited to, the factors described in greater detail in the "Risks
and Uncertainties" section of our management's discussion and
analysis of financial condition and results of operations for the
three and nine months ended June 30,
2022, which is available on the Company's profile at
www.sedar.com, any of which could cause results,
performance, or achievements to differ materially from the results
discussed or implied in the forward-looking statements. Investors
should not place undue reliance on any forward-looking statements.
The forward-looking statements contained in this news release are
made as of the date of this news release, and the Company assumes
no obligation to update or alter any forward-looking statements,
whether as a result of new information, further events or
otherwise, except as required by law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/covalon-to-participate-in-the-12th-international-pediatric-intestinal-failure-and-rehabilitation-symposium-in-toronto-301635567.html
SOURCE Covalon Technologies Ltd.